Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
The chemokine receptor CCR5 provides a portal of entry for human immunodeficiency virus type 1 (HIV-1) into susceptible CD4(+) cells. Both monoclonal antibody (MAb) and small-molecule CCR5 inhibitors have entered human clinical testing, but little is known regarding their potential interactions. We evaluated the interactions between CCR5 MAbs, small-molecule CCR5 antagonists, and inhibitors of HIV-1 gp120, gp41, and reverse transcriptase in vitro. Inhibition data were analyzed for cooperative effects using the combination index (CI) method and stringent statistical criteria. Potent, statistically significant antiviral synergy was observed between the CCR5 MAb PRO 140 and the small-molecule CCR5 antagonists maraviroc (UK-427,857), vicriviroc (SCH-D), and TAK-779. High-level synergy was observed consistently across various assay systems, HIV-1 envelopes, CCR5 target cells, and inhibition levels. CI values ranged from 0.18 to 0.64 and translated into in vitro dose reductions of up to 14-fold. Competition binding studies revealed nonreciprocal patterns of CCR5 binding by MAb and small-molecule CCR5 inhibitors, suggesting that synergy occurs at the level of receptor binding. In addition, both PRO 140 and maraviroc synergized with the chemokine RANTES, a natural ligand for CCR5; however, additive effects were observed for both small-molecule CCR5 antagonists and PRO 140 in combination with other classes of HIV-1 inhibitors. The findings provide a rationale for clinical exploration of MAb and small-molecule CCR5 inhibitors in novel dual-CCR5 regimens for HIV-1 therapy.
Murga
Jose D
JD
Progenics Pharmaceuticals, Inc, Tarrytown, NY 10591, USA.
Franti
Michael
M
Pevear
Daniel C
DC
Maddon
Paul J
PJ
Olson
William C
WC
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D001667:Binding, Competitive; D065100:CCR5 Receptor Antagonists; D002460:Cell Line; D003510:Cyclohexanes / Q000378:metabolism / Q000494:pharmacology*; D004357:Drug Synergism; D015483:HIV Antibodies / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015700:HIV Envelope Protein gp41 / Q000378:metabolism; D023581:HIV Fusion Inhibitors / Q000276:immunology / Q000378:metabolism / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006367:HeLa Cells; D006801:Humans; D000077592:Maraviroc; D008561:Membrane Fusion / Q000187:drug effects; D010879:Piperazines / Q000378:metabolism / Q000494:pharmacology*; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology*; D019713:Receptors, CCR5 / Q000276:immunology; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism / Q000494:pharmacology; D014230:Triazoles / Q000378:metabolism / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D019713:Receptors, CCR5; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; D000077592:Maraviroc; C486781:vicriviroc; C420063:leronlimab